Sarepta Therapeutics (SRPT) PT Raised to $112 at RBC Capital

RBC Capital raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $112.00 (from $98.00) while maintaining an Outperform rating.

Analyst Brian Abrahams commented, "following a deep dive into the mechanism, preclinical data, competitive landscape, and mkt oppty for gene therapies in Duchenne muscular dystrophy (DMD), we are increasingly enthusiastic about the potential for SRPT's microdystrophin program and the likelihood they will report favorable initial NT results that will drive substantial stock upside."

You May Also Be Interested In

• Natera (NTRA) PT Raised to $460 at RBC Capital on 'Strong Setup'
• Okta, Inc (OKTA) PT Raised to $230 at BMO Capital on 'AI and Virtuous Cycle Opportunity'
• Nutex Health (NUTX) PT Raised to $306 at Freedom Capital